Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Harvard Business School
Cerilliant
QuintilesIMS
Teva
Cantor Fitzgerald
Merck
Queensland Health

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,544,372

« Back to Dashboard

Which drugs does patent 7,544,372 protect, and when does it expire?

Patent 7,544,372 protects AMRIX and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 7,544,372
Title:Modified release dosage forms of skeletal muscle relaxants
Abstract:A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s): Venkatesh; Gopi (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee: Eurand, Inc. (Vandalia, OH)
Application Number:12/026,887
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,544,372
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,544,372

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial RELIEF OF MUSCLE SPASM ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial RELIEF OF MUSCLE SPASM ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,544,372

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,829,121 Modified release dosage forms of skeletal muscle relaxants ➤ Try a Free Trial
9,375,410 Modified release dosage forms of skeletal muscle relaxants ➤ Try a Free Trial
9,399,025 Modified release dosage forms of skeletal muscle relaxants ➤ Try a Free Trial
7,387,793 Modified release dosage forms of skeletal muscle relaxants ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
Harvard Business School
Express Scripts
Federal Trade Commission
Colorcon
Chinese Patent Office
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.